Afrezza — Strategic Intervention
Afrezza, an ultra-rapid-acting inhaled insulin approved by the FDA in June 2014, entered the diabetes marketplace with exceptionally high pre-launch expectations driven by its rapid…
Entresto: When Clinical Strength Was Not Enough
Entresto entered the market with significant clinical promise and the potential to reshape heart failure management.
Commercialization Strategy Discussion
Pressure-test launch assumptions, commercialization plans, and market readiness with an experienced pharmaceutical launch strategist.

